PT - JOURNAL ARTICLE AU - Rohan Khera AU - Yongfei Wang AU - Susannah M. Bernheim AU - Zhenqiu Lin AU - Sharon-Lise T. Normand AU - Harlan M. Krumholz TI - Evaluation of the Hospital Readmissions Reduction Program AID - 10.1101/19011734 DP - 2019 Jan 01 TA - medRxiv PG - 19011734 4099 - http://medrxiv.org/content/early/2019/11/12/19011734.short 4100 - http://medrxiv.org/content/early/2019/11/12/19011734.full AB - Background There is conflicting evidence about whether the Hospital Readmission Reduction Program (HRRP) is associated with an increase in mortality.Methods In a cohort of Medicare beneficiaries hospitalized with heart failure (HF), we compared two published approaches to evaluating the association of HRRP and risk-adjusted 30-day mortality, including changes in average mortality across periods and changes in slope of monthly mortality rates across discrete periods. We also tested various methods with simulated data that was designed with an inflection in mortality.Results We identified 4,313,523 hospitalizations for HF, 1,788,219 for AMI, and 3,758,111 for pneumonia. Monthly slope-change models identified an increase in mortality for HF and pneumonia in the pre-HRRP period (P<.001 for slope-change). The changes in average mortality across the four time periods model found an increase in mortality for HF and pneumonia in the HRRP anticipation period (post-announcement, pre-implementation) as well as following HRRP implementation. However, under those conditions, our simulations reveal that method errs in identifying the timing of a change. Varying the data sources and risk-adjustment strategies had no significant effect on the results.Conclusion A national policy incentivizing efforts to reduce readmission did not increase the risk of mortality.Competing Interest StatementDrs. Krumholz, Normand, Bernheim, Lin, and Mr. Wang work under contract with the Centers for Medicare & Medicaid Services to develop publicly reported quality measures. Dr. Krumholz was a recipient of a research grant, through Yale, from Medtronic and the U.S. Food and Drug Administration to develop methods for post-market surveillance of medical devices; is a recipient of a research grant with Medtronic and Johnson & Johnson, through Yale, to develop methods of clinical trial data sharing; was a recipient of a research agreement, through Yale, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; received payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation; receives payment from the Siegfried & Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the founder of HugoHealth, a personal health information platform and a co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company. Dr. Khera reports no potential conflicts of interest. The study was conceived and conducted by the authors, and the Centers for Medicare & Medicaid Services played no role in its design and conduct; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Funding StatementDr. Khera is supported by the National Center for Advancing Translational Sciences (UL1TR001105) of the National Institutes of Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are proprietary of the Centers for Medicare and Medicaid Services (CMS), and can be obtained from them directly under a data use agreement with them.